Morgan Stanley analyst Terence Flynn maintains $AbbVie (ABBV.US)$ with a buy rating, and adjusts the target price from $218 to $231.
According to TipRanks data, the analyst has a success rate of 56.3% and a total average return of 9.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $AbbVie (ABBV.US)$'s main analysts recently are as follows:
After AbbVie reported robust third-quarter results and increased its revenue guidance for 2024, the company's outlook towards the end of the year is viewed positively. The improved projection for 2025 earnings per share has influenced this optimistic stance. Nonetheless, when assessing the company's long-term growth prospects in relation to its present valuation, a neutral perspective is maintained.
Following a robust third-quarter report which exceeded expectations, confidence in the growth outlook is fortified, particularly with commentary looking ahead to 2025. This sentiment is reinforced by upward revisions in estimates, largely driven by anticipated increases in Rinvoq/Skyrizi sales, though somewhat balanced by a tempered forecast for aesthetics and Humira sales.
The company has reported another robust quarter, which supports a positive outlook on the stock. This optimism is bolstered by numerous upcoming pipeline events and strong commercial traction heading into 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
摩根士丹利分析師Terence Flynn維持$艾伯維公司 (ABBV.US)$買入評級，並將目標價從218美元上調至231美元。
根據TipRanks數據顯示，該分析師近一年總勝率為56.3%，總平均回報率為9.5%。
此外，綜合報道，$艾伯維公司 (ABBV.US)$近期主要分析師觀點如下：
在艾伯維公司報告強勁的第三季度業績並增加了2024年營業收入指引之後，公司對年底的展望被積極看待。對2025年每股收益的改善預期影響了這種樂觀態度。然而，在評估公司長期增長前景與目前估值的關係時，仍保持中立觀點。
在第三季度強勁的報告之後，超出預期，對增長前景的信心得到了加強，特別是在展望2025年時。此情緒的增強得到了估值的上調支持，主要是由於預期Rinvoq/Skyrizi銷售的增加，儘管在美學和Humira銷售的預測方面受到一定平衡的影響。
公司報告了另一個強勁的季度，這支持着對股票的積極展望。這種樂觀情緒得到了許多即將到來的管線活動和2025年強勁的商業動力的支持。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
